Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: A review

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 725-738

  Monnier, Alain ^a  

^a Traumatologie du Centre Hospitalier de Belfort Montbéliard Site de Montbéliard   (France)

Author keywords

Aromatase inhibitor; Breast cancer; Hormonal therapy; Letrozole; Postmenopausal women; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CHOLESTEROL; ESTRADIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE; EXEMESTANE; HIGH DENSITY LIPOPROTEIN; LETROZOLE; LOW DENSITY LIPOPROTEIN; TAMOXIFEN; TRIACYLGLYCEROL; ZOLEDRONIC ACID;

ARTHRALGIA; ARTHRITIS; ARTHROPATHY; BONE PAIN; BONE TURNOVER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; EARLY CANCER; ENDOMETRIUM CANCER; ESTROGEN BLOOD LEVEL; FRACTURE; FRAGILITY FRACTURE; GYNECOLOGIC DISEASE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LETHALITY; MOOD CHANGE; MUSCULOSKELETAL DISEASE; MYALGIA; NIGHT SWEAT; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STROKE; SWEATING; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL; VAGINA BLEEDING; VAGINAL DRYNESS; VERBAL MEMORY;

EID: 75749110468     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s3858     Document Type: Review

References (64)

1. Aiello EJ, Buist DS, Wagner EH, et al. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat. 2008;107:397-403.
2. Thurlimann B, Keshaviah A, Coates AS, et al. Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and TAMOXIFEN in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747-2757.
3. Thurlimann B. Letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Update of the BIG 1-98 Primary Core Analysis (PCA). Presented at the 39th St. Gallen Symposium; May 7-9, 2009; St. Gallen, Switzerland. Abstract 0161.
4. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25:486-492.
5. Mouridsen H; on behalf of the IBCSG BIG 1-98 trial group. Letrozole monotherapy vs tamoxifen monotherapy or vs letrozole in sequence with tamoxifen for postmenopausal women with endocrine-responsive early breast cancer. Cancer Res. 2009;69 Suppl 2:66s. Abstract 13.
6. Howell A, Cuzick J, Baum M, et al. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60-62.
7. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45-53.
8. Coombes RC, Hall E, Gibson LJ, et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-1092.
9. Coombes RC, Kilburn LS, Snowdon CF, et. al. Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559-570.
10. Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol. 2007;25:2664-2670.
11. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol. 2005;23:5138-5147.
12. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-1802.
13. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262-1271.
14. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18:937-947.
15. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90: 1371-1388.
16. Geisler J, Helle H, Ekse D, et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res. 2008;14:6330-6335.
17. Dixon JM, Renshaw L, Young O, et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008;26:1671-1676.
18. Rossi E, Morabito A, Di Rella F, et al. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: The HOBOE Trial. J Clin Oncol. 20 April 2009 [Epub ahead of print]. 10.1200/JCO.2008.18.6213. Available at: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2008.18.6213.
19. Mauriac L, Keshaviah A, Debled M, et al. BIG 1-98 Collaborative Group; International Breast Cancer Study Group. Predictors of early relapse in postmenopausal women with hormone receptorpositive breast cancer in the BIG 1-98 trial. Ann Oncol. 2007;18:859-867.
20. Lamerato S, Havstad S, Gandhi D, Jones R. Chlebowski. Breast cancer recurrence and related mortality in US pts with early breast cancer. J Clin Oncol. 2005;23(16S):62s. Abstract 738.
21. Mansell J, Monypenny IJ, Skene AI, et al. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2008 Dec 27. [Epub ahead of print].
22. Houghton J. Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T) - data reported on behalf of the ATAC ('Arimidex', tamoxifen, alone or in Combination) Trialists' group. Ann Oncol. 2006;17 Suppl 9:ix94. Abstract 243PD.
23. Rugo HS. Adjuvant therapies: distant disease-free survival as a predictor of overall survival. Presented at: Primary Therapy of Early Breast Cancer 2007: 10th International Conference; March 14-17, 2007; St. Gallen, Switzerland. Abstract 120.
24. Monnier A. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial. Expert Rev Anticancer Ther. 2006; 6:1355-1359.
25. O'Shaughnessy J. A decade of letrozole: FACE. Breast Cancer Res Treat. 2007;105 Suppl 1:67-74.
26. Hortobagyi GN, Kau SW, Buzdar AU, et al. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? Proc Am Soc Clin Oncol. 2004;22(14S):Abstract 585.
27. Ingle JN, Tu D, Pater JL, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat. 2006;99:295-300.
28. Ingle JN, Tu D, Pater JL, et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol. 2008;19:877-882.
29. Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008;26: 1948-1955. Erratum in: J Clin Oncol. 2008;26:3659.
30. Cuzick J, Allen D, Baum M, et al. Long term effects of tamoxifen. Biological effects of Tamoxifen Working Party. Eur J Cancer. 1992;29A:15-21.
31. Love RR, Mazess RB, Barden HS, et al. Effects of TAMOXIFEN on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-856.
32. Kristensen B, Ejlertsen B, Dalgaard P, et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol. 1994;12:992-997.
33. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant TAMOXIFEN for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ. 1995;311:977-980.
34. Monnier A. The effects of adjuvant aromatase inhibitor therapy on lipid profiles. Expert Rev Anticancer Ther. 2006;6:1653-1662.
35. Monnier A. Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer. Ann Oncol. 2007; 18 Suppl 8:viii 36-44.
36. Garreau JR, Delamelena T, Walts D, Karamlou K, Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective. Am J Surg. 2006;192:496-498.
37. Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 2007;25:5715-5722.
38. Wasan KM, Goss PE, Pritchard PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant TAMOXIFEN (NCIC CTG MA.17L). Ann Oncol. 2005;16:707-715.
39. Buzdar A, Howell A, Cuzick J, et al. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7:633-643.
40. McCaig F, Renshaw L, Williams L, et al. A randomised study comparing the effects of anastrozole and letrozole on lipid metabolism. Cancer Res. 2009;69 Suppl 2:150s-151s. Abstract 1152.
41. McCaig F, Renshaw L, Williams L, et al. A randomised study of the effects of letrozole and anastrozole on bone turnover. Breast Cancer Res Treat. 2007;106 Suppl 1:S109. Abstract 2074.
42. McCaig F, Renshaw L, Williams L, et al. A randomized study of the effects of anastrozole (A), letrozole (L), and exemestane (E) on bone. Cancer Res. 2009;69 Suppl 2:148s. Abstract 1145.
43. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25:829-836.
44. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer. 2008;112:1001-1010.
45. Brufsky A, Bosserman L, Caradonna R, et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-month follow-up. Breast Cancer Res Treat. 2007;106 Suppl 1:S8. Abstract 27.
46. Eidtmann H, Bundred N, DeBoer R, et al. The Effect of Zoledronic Acid on Aromatase Inhibitor Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Letrozole: 36 Months Follow-up of ZO-FAST. Cancer Res. 2009;69 Suppl 2:74s. Abstract 44.
47. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic Acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25:820-828.
48. Gnant MB, Mlineritsch W, Schippinger G, et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormoneresponsive, stage I and II breast cancer: First efficacy results from ABCSG-12. J Clin Oncol. 2008:26 Suppl:1006s. Abstract LBA4.
49. Cuzick J, Sestak I, Cella D, et al. ATAC Trialists' Group. Treatmentemergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol. 2008;9:1143-1148.
50. Renshaw L, McHugh RGN, Williams L, et al. Comparison of joint problems reported by patients in a randomized adjuvant trial of anastrozole and letrozole. Breast Can Res Treat. 2007;106 Suppl 1: S108-S109. Abstract 2072.
51. Briot K, Bastit L, Rotarsky M, et al. Effects of switching aromatase inhibitors on arthralgia: the ATOLL study. Cancer Res. 2008; 69 Suppl:147s-148s. Abstract 1142.
52. Markou A, Duka T, Prelevic GM. Estrogens and brain function. Hormones (Athens). 2005;4:9-17.
53. Spencer JL, Waters EM, Romeo RD, Wood GE, Milner TA, McEwen BS. Uncovering the mechanisms of estrogen effects on hippocampal function. Front Neuroendocrinol. 2008;29:219-237.
54. Singh M, Dykens JA, Simpkins JW. Novel mechanisms for estrogen-induced neuroprotection. Exp Biol Med (Maywood). 2006;231:514-521.
55. Rugo HS, Ahles T. The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Semin Oncol. 2003;30:749-762.
56. Shilling V, Jenkins V, Fallowfield L, Howell T. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol. 2003;86:405-412.
57. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004;13:61-66.
58. Debess J, Riis JØ, Pedersen L, Ewertz M. Cognitive function and quality of life after surgery for early breast cancer in North Jutland, Denmark. Acta Oncol. 2009;48:532-540.
59. ClinicalTrials.gov Identifier: NCT00687102. Effects of selective estrogen receptor modulators on cognitive aging: cognition in the study of tamoxifen and raloxifene. Available from: http://clinicaltrials.gov/ct2/show/NCT00687102.
60. Bender CM, Sereika SM, Brufsky AM, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause. 2007;14:995-998.
61. Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005;23:6931-6940.
62. Abetz L, Brandman J, Barghout V, de la Loge C, Arbuckle R. No differences in quality of life for letrozole relative to placebo in postmenopausal women with early breast cancer regardless of age: results from the MA-17 study. Eur J Cancer Suppl. 2005;3:96. Abstract 342.
63. Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol. 2006;24:910-917.
64. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A; ATAC Trialists' Group. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006;100:273-284.